Search results
Showing 1151 to 1200 of 2052 results for work
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]
Discontinued Reference number: GID-TA10382
Discontinued Reference number: GID-TA10422
Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]
Discontinued Reference number: GID-TAG232
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Discontinued Reference number: GID-TAG300
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
Discontinued Reference number: GID-TAG332
Discontinued Reference number: GID-TA10803
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued Reference number: GID-TA10177
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
Discontinued Reference number: GID-TA10242
Temozolomide for the treatment of advanced and metastatic melanoma [ID316]
Discontinued Reference number: GID-TAG401
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued Reference number: GID-TA11244
Venous thromboembolism - apixaban (acute medical illness) [ID310]
Discontinued Reference number: GID-TAG419
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
Discontinued Reference number: GID-TA11204
Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.
View recommendations for HTG689Show all sections
Discontinued Reference number: GID-TA10543
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
Discontinued Reference number: GID-TA10341
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
Discontinued Reference number: GID-TA10464
Discontinued Reference number: GID-TA10166
In development Reference number: GID-TA11433 Expected publication date: TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
Discontinued Reference number: GID-TAG526
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued Reference number: GID-TA10480
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Discontinued Reference number: GID-TA10536
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued Reference number: GID-TA10539
Discontinued Reference number: GID-TA10365
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued Reference number: GID-TAG321
Discontinued Reference number: GID-TA10628
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
Discontinued Reference number: GID-TA10923
Discontinued Reference number: GID-TA10171
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued Reference number: GID-TA10193
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Discontinued Reference number: GID-TA11264
Discontinued Reference number: GID-TA11026
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Discontinued Reference number: GID-TA11000
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Discontinued Reference number: GID-TA10851
Discontinued Reference number: GID-SGWAVE0702
Discontinued Reference number: GID-SGWAVE0761
Discontinued Reference number: GID-SGWAVE0700
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development Reference number: GID-TA10779 Expected publication date: TBC
Discontinued Reference number: GID-SGWAVE0762
Discontinued Reference number: GID-SGWAVE0701
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Discontinued Reference number: GID-TA10310
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]
Discontinued Reference number: GID-TAG337
Discontinued Reference number: GID-TA10591